The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

Auteurs

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J

  • Date de publication

    June 2025

  • Type

    Article

  • Review

    ESMO Open

  • Researcher's name

    PICCART MARTINE

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    40460679

  • DOI

    10.1016/j.esmoop.2025.105294